PTK2 and non-small cell lung carcinoma: Another Phase I study (NCT02758587) investigated the combination of defactinib (a FAK inhibitor) and pembrolizumab (a PD-1 inhibitor) in patients with non-small cell lung cancer (NSCLC), mesothelioma, and pancreatic neoplasms.